EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Real-World Candidacy to Mavacamten in a Contemporary Hypertrophic Obstructive Cardiomyopathy Population

Edoardo Bertero, Chiara Chiti, Maria Alessandra Schiavo, Giacomo Tini, Paolo Costa, Giancarlo Todiere, Barbara Mabritto, Lorenzo-Lupo Dei, Alessia Giannattasio, Davide Mariani, Carla Lofiego, Caterina Santolamazza und 48 weitere

European Journal of Heart Failure · 01.01.2024 · 26 (1) · 59-64

DOI: 10.1002/ejhf.3120 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Heart Failure, online erschienen am 02.01.2024. Verfasst von Edoardo Bertero und 59 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Unit, Department of Internal Medicine, University of Genova, Genova, Italy. Hauptthemen laut MEDLINE: Benzylamines, Cardiomyopathy, Hypertrophic, Heart Failure, Uracil. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In the EXPLORER-HCM trial, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved functional capacity of symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients. We sought to define the potential use of mavacamten by comparing real-world HOCM patients with those enrolled in EXPLORER-HCM and assessing their eligibility to treatment. Methods and results We collected information on HOCM patients followed up at 25 Italian HCM outpatient clinics and with significant LVOTO (i.e. gradient ≥30 mmHg at rest or ≥50 mmHg after Valsalva manoeuvre or exercise) despite pharmacological or non-pharmacological therapy. Pharmacological or non-pharmacological therapy resolved LVOTO in 1044 (61.2%) of the 1706 HOCM patients under active follow-up, whereas 662 patients (38.8%) had persistent LVOTO. Compared to the EXPLORER-HCM trial population, these real-world HOCM patients were older (62.1 ± 14.3 vs. 58.5 ± 12.2 years, p = 0.02), had a lower body mass index (26.8 ± 5.3 vs. 29.7 ± 4.9 kg/m2, p < 0.0001) and a more frequent history of atrial fibrillation (21.5% vs. 9.8%, p = 0.027). At echocardiography, they had lower left ventricular ejection fraction (LVEF, 66 ± 7% vs. 74 ± 6%, p < 0.0001), higher left ventricular outflow tract gradients at rest (60 ± 27 vs. 52 ± 29 mmHg, p = 0.003), and larger left atrial volume index (49 ± 16 vs. 40 ± 12 ml/m2, p < 0.0001). Overall, 324 (48.9%) would have been eligible for enrolment in the EXPLORER-HCM trial and 339 (51.2%) for treatment with mavacamten according to European guidelines.

Conclusions

Real-world HOCM patients differ from the EXPLORER-HCM population for their older age, lower LVEF and larger atrial volume, potentially reflecting a more advanced stage of the disease. About half of real-world HOCM patients were found eligible to mavacamten.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzylaminesCardiomyopathy, HypertrophicHeart FailureUracilHumansStroke VolumeVentricular Function, Left

Stichwörter der Autor:innen

EXPLORER-HCM trialHypertrophic obstructive cardiomyopathyMavacamtenMyosin inhibitors

Substanzen

BenzylaminesMYK-461Uracil

Autor:innen und Institutionen

  • Cardiovascular Unit, Department of Internal Medicine, University of Genova, Genova, Italy.
  • Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.
  • Cardiology Unit, Cardio-Thoraco-Vascular Department, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
  • European Reference Network for Rare, Low Prevalence, and Complex Diseases of the Heart (ERN GUARD-Heart).
  • Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Cardiothoracic Department, Fondazione Toscana Gabriele Monasterio Pisa, Pisa, Italy.

Zitieren

APA

Bertero, E., Chiti, C., Schiavo, M. A., Tini, G., Costa, P., Todiere, G., Mabritto, B., Dei, L. L., Giannattasio, A., Mariani, D., Lofiego, C., Santolamazza, C., Monda, E., Quarta, G., Barbisan, D., Mandoli, G. E., Mapelli, M., Sguazzotti, M., Negri, F., …, & Biagini, E. (2024). Real-World Candidacy to Mavacamten in a Contemporary Hypertrophic Obstructive Cardiomyopathy Population. European Journal of Heart Failure, 26(1), 59-64. https://doi.org/10.1002/ejhf.3120

Vancouver

Bertero E, Chiti C, Schiavo MA, Tini G, Costa P, Todiere G, et al. Real-World Candidacy to Mavacamten in a Contemporary Hypertrophic Obstructive Cardiomyopathy Population. European Journal of Heart Failure. 2024;26(1):59-64. doi:10.1002/ejhf.3120

BibTeX
@article{Bertero2024,
  author = {Bertero, Edoardo and Chiti, Chiara and Schiavo, Maria Alessandra and Tini, Giacomo and Costa, Paolo and Todiere, Giancarlo and Mabritto, Barbara and Dei, Lorenzo-Lupo and Giannattasio, Alessia and Mariani, Davide and Lofiego, Carla and Santolamazza, Caterina and Monda, Emanuele and Quarta, Giovanni and Barbisan, Davide and Mandoli, Giulia Elena and Mapelli, Massimo and Sguazzotti, Maurizio and Negri, Francesco and De Vecchi, Simona and Ciabatti, Michele and Tomasoni, Daniela and Mazzanti, Andrea and Marzo, Francesca and de Gregorio, Cesare and Raineri, Claudia and Vianello, Pier Filippo and Marchi, Alberto and Biagioni, Giulia and Insinna, Eleonora and Parisi, Vanda and Ditaranto, Raffaello and Barison, Andrea and Giammarresi, Andrea and De Ferrari, Gaetano Maria and Priori, Silvia and Metra, Marco and Pieroni, Maurizio and Patti, Giuseppe and Imazio, Massimo and Perugini, Enrica and Agostoni, Piergiuseppe and Cameli, Matteo and Merlo, Marco and Sinagra, Gianfranco and Senni, Michele and Limongelli, Giuseppe and Ammirati, Enrico and Vagnarelli, Fabio and Crotti, Lia and Badano, Luigi and Calore, Chiara and Gabrielli, Domenico and Re, Federica and Musumeci, Giuseppe and Emdin, Michele and Barbato, Emanuele and Musumeci, Beatrice and Autore, Camillo and Biagini, Elena},
  title = {Real-World Candidacy to Mavacamten in a Contemporary Hypertrophic Obstructive Cardiomyopathy Population},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {1},
  pages = {59--64},
  doi = {10.1002/ejhf.3120}
}
Kostenlos starten →